Bisphosphonates suppress the breakdown of bone, which improves bone density. They were first used to treat osteoporosis and later noted to help with bone metastases. Bisphosphonates are also approved ...

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.

Zoledronic acid has several advantages over other bisphosphonates ... recommended zoledronic acid dose for the treatment of bone metastases is 4 mg by IV infusion, infused over no less than ...

Bone metastases are cancers that have spread (metastasized) from other tissues in the body through the blood or lymphatic systems to the bone marrow. Bone metastases form the main type of bone ...

we explored the effect of bone-modifying agents (bisphosphonates such as zoledronic acid and denosumab) on OS and progression-free survival in patients with mCRPC with at least 1 bone metastasis using ...

Nevertheless, the specific function of MAFG-DT in the context of bone metastasis in PCa remains inadequately understood. Methods: The expression level of MAFG-DT was analyzed in published datasets and ...

Xgeva (denosumab) has already been approved to treat fractures in patients with multiple myeloma without bone metases, and in patients with bone metastases from solid tumours. It is also indicated ...

6. Bone-Modifying Drugs The addition of bisphosphonate therapy has been considered in early-stage breast cancer, as it may reduce the risk for bone metastases. With metastatic breast cancer, systemic ...

To determine which parameters, including femur morphology, proximal femur bone mineral density, or patient characteristics, are associated with bisphosphonate-related atypical femur fractures (AFFs) ...